InDex Pharmaceuticals Will Be Granted U.S. Patent for Kappaproct to Treat Ulcerative Colitis

InDex Pharmaceuticals Will Be Granted U.S. Patent for Kappaproct to Treat Ulcerative Colitis
InDex Pharmaceuticals will be granted a U.S. patent covering the use of certain dosage regimens of its investigational drug Kappaproct (cobitolimod) for the treatment of moderate-to-severe active ulcerative colitis (UC) in patients not responding to available therapies. The United States Patent and Trademark Office will issue the patent called “Method for prevention of colestomy” (number 9492516) on

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *